Oppenheimer downgraded Hamilton Lane from Outperform to Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/16/2026 | $166.00 | Neutral → Overweight | Analyst |
| 12/11/2025 | $166.00 | Buy | UBS |
| 11/6/2025 | $165.00 | Neutral → Buy | Goldman |
| 10/14/2025 | $181.00 | Perform → Outperform | Oppenheimer |
| 10/13/2025 | $150.00 | Mkt Perform → Outperform | Keefe Bruyette |
| 10/3/2025 | $150.00 | Outperform | BMO Capital Markets |
| 9/18/2025 | $162.00 | Sell → Neutral | Goldman |
| 5/15/2025 | Outperform → Perform | Oppenheimer |
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
SCHEDULE 13D/A - Hamilton Lane INC (0001433642) (Subject)
10-K - Hamilton Lane INC (0001433642) (Filer)
8-K - Hamilton Lane INC (0001433642) (Filer)
CONSHOHOCKEN, Pa., May 21, 2026 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth quarter and full fiscal year ended March 31, 2026. The Company issued a full detailed presentation of its fourth quarter and full fiscal year 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/.DividendHamilton Lane has declared a quarterly dividend of $0.60 per share of Class A common stock to record holders at the close of business on June 18, 2026 that will be paid on July 7, 2026. The target full-year dividend of $2.40 represents a 11% increase from t
— Proven biopharmaceutical executive to lead commercial strategy as Cosette scales its branded pharmaceutical platform and advances its next phase of growth — Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer (Brands). David joins the company's executive leadership team as it continues to advance its ambitions in specialty pharmaceuticals and expand its commercial platform and portfolio. In this new role, David will oversee all branded commercial functions – including sales, marketing, market access, commercial operations, analytics, and portfolio strategy. He will be responsible
MidOcean Partners ("MidOcean"), a premier New York-based alternative asset manager specializing in middle-market private equity, alternative credit, and structured equity, today announced the closing of a single-asset continuation vehicle for Cloyes Gear and Products, Inc. ("Cloyes" or the "Company"), the North American leader and global designer, developer, manufacturer, and distributor of mission-critical timing drive systems and components for the automotive aftermarket. The continuation vehicle secured approximately $300 million in commitments, with funds managed by Hamilton Lane (NASDAQ:HLNE) serving as sole lead investor. In connection with the continuation vehicle, MidOcean-managed
Analyst upgraded Hamilton Lane from Neutral to Overweight and set a new price target of $166.00
UBS resumed coverage of Hamilton Lane with a rating of Buy and set a new price target of $166.00
Goldman upgraded Hamilton Lane from Neutral to Buy and set a new price target of $165.00
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
— Proven biopharmaceutical executive to lead commercial strategy as Cosette scales its branded pharmaceutical platform and advances its next phase of growth — Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer (Brands). David joins the company's executive leadership team as it continues to advance its ambitions in specialty pharmaceuticals and expand its commercial platform and portfolio. In this new role, David will oversee all branded commercial functions – including sales, marketing, market access, commercial operations, analytics, and portfolio strategy. He will be responsible
-- Experienced life sciences executive to lead legal, compliance, and governance as Cosette scales its platform following recent acquisitions and continued growth momentum -- Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today that it has appointed Erika Tooman as Senior Vice President and General Counsel, strengthening the company's executive leadership team as it advances its long‑term growth, portfolio expansion, and value‑creation strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429022652/en/ Erika brings more than two decades of experience guiding pharmaceutica
Expanded institutional participation underscores growing demand for private market opportunities and standardized operating infrastructureNEW YORK, March 9, 2026 /PRNewswire/ -- Corastone, the hyperscaler for private-market investing, today announced Fidelity Investments, Future Standard, and Hamilton Lane (NASDAQ:HLNE) as investors in Corastone and its alternative-investing operating platform. This growing institutional participation builds on Corastone's recent platform launch and comes as demand for private markets investments expands across investor types. As global private
CONSHOHOCKEN, Pa., May 21, 2026 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth quarter and full fiscal year ended March 31, 2026. The Company issued a full detailed presentation of its fourth quarter and full fiscal year 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/.DividendHamilton Lane has declared a quarterly dividend of $0.60 per share of Class A common stock to record holders at the close of business on June 18, 2026 that will be paid on July 7, 2026. The target full-year dividend of $2.40 represents a 11% increase from t
CONSHOHOCKEN, Pa., April 23, 2026 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2026 before the market opens on Thursday, May 21, 2026. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website. Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on May 21 to discuss the results for the fourth fiscal quarter and full fiscal year. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here at least 15 minutes prior to the start of the call. This f
CONSHOHOCKEN, Pa. and NEW YORK, March 17, 2026 /PRNewswire/ -- Hamilton Lane (NASDAQ:HLNE), a leading global private markets investment firm, today announced a strategic investment in Republic, a leading on-chain global investment platform, reinforcing the firms' shared commitment to expanding retail investor access to institutional-quality private market funds. The investment builds on the existing partnership between Hamilton Lane and Republic, and underscores Hamilton Lane's long-term strategy to modernize and expand access to private markets. Together, the firms are enabling broader participation in the private markets asset class, which has historically been limited to institutions and
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)